Form 4: Immunovant CFO Sells Shares to Cover Tax Obligations After RSU Vesting

Eva Renee Barnett, CFO of Immunovant, Inc., sold 4,747 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On July 9, 2024, Eva Renee Barnett, the Chief Financial Officer of Immunovant, Inc., sold 4,747 shares of Immunovant's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of 8,937 restricted stock units (RSUs) on July 4, 2024.
• The shares were sold at a weighted average price of $28.06, with individual transactions ranging from $27.48 to $28.42 per share.
• Following the transaction, Barnett directly owns 350,667 shares of Immunovant common stock.
• The sale was mandated by Immunovant's policy requiring tax obligations to be funded through a 'sell to cover' transaction, indicating it was not a discretionary sale by Barnett.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (sell to cover taxes) and doesn't suggest any negative sentiment towards the company. The CFO still holds a significant number of shares.

Positives

• The transaction is a standard 'sell to cover' to meet tax obligations, which is a common practice.
• The CFO still holds a significant number of shares (350,667) after the sale, indicating continued alignment with the company's success.

Future Outlook

There are no specific forward-looking statements in this document.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among executives in publicly traded companies. This transaction is not indicative of a change in the company's outlook or the executive's confidence in the company.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time.
• Upon vesting, these RSUs are subject to income tax, and executives commonly sell a portion of the shares to cover these tax obligations.
• This 'sell to cover' strategy is a standard practice and doesn't necessarily reflect a negative sentiment towards the company's future prospects.
• Comparing Immunovant's executive compensation structure and practices to those of similar biotech companies would provide further context, but this information is not available in the provided document.

Stakeholder Impact

• The sale of shares could have a minor, temporary impact on the stock price, but it is unlikely to be significant given the nature of the transaction.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates